CoChat
Sign Up
Cited by 410Iron Metabolism and DisordersErythropoietin and Anemia TreatmentHemoglobinopathies and Related Disorders

Detection, evaluation, and management of iron-restricted erythropoiesis

Open access
Goodnough, Lawrence Tim, Nemeth, Elizabeta, Ganz, Tomas·2010·Blood
DOI 10.1182/blood-2010-05-286260
Open this paper in CoChat — free accountOpen PDF

Abstract

Progress in our understanding of iron-restricted erythropoiesis has been made possible by important advances in defining the molecular mechanisms of iron homeostasis. The detection and diagnostic classification of iron-restricted erythropoiesis can be a challenging process for the clinician. Newer assays for markers of inflammation may allow more targeted management of the anemia in these conditions. The availability of new intravenous iron preparations provides new options for the treatment of iron-restricted erythropoiesis. This review summarizes recent advances regarding the detection, evaluation, and management of iron-restricted erythropoiesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-05-286260

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Infection and inflammation induce hepcidin production, which lowers plasma iron by inhibiting iron absorption and promoting iron sequestration in macrophages.

    “Infection and inflammation induce hepcidin production, driving a decrease in plasma iron concentrations by inhibiting the absorption of iron and promoting the sequestration of iron in macrophages.”

    From Iron homeostasis in host defence and inflammation (2015) · cites this paper as [27]

  • Prolonged activation of hepcidin during infection and inflammation causes anaemia of inflammation, partly by restricting iron supply to the erythropoietic bone marrow.

    “Prolonged activation of this mechanism during infection and inflammation imposes a biological cost in the form of anaemia of inflammation27–29, a condition that is partly caused by the restriction of iron supply to the erythropoietic bone marrow.”

    From Iron homeostasis in host defence and inflammation (2015) · cites this paper as [27]

  • The increase in hepcidin secretion in response to infectious or inflammatory stimuli is responsible for the characteristic hypoferraemia of inflammation.

    “The increase in hepcidin secretion in response to infectious or inflammatory stimuli is responsible for the characteristic hypoferraemia of inflammation26,27, which develops within a few hours of a systemic infection or following injection of microbial components or certain cytokines.”

    From Iron homeostasis in host defence and inflammation (2015) · cites this paper as [27]

  • Typically, iron deficiency anemia is an isolated hyporegenerative microcytic hypochromic anemia, with reduced ferritin concentration and transferrin saturation.

    “Typically, IDA is an isolated hyporegenerative microcytic hypochromic anemia, with reduced FT concentration and TSAT as indicators of a depletion of iron stores and serum iron, respectively [12–15].”

    From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [13]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 65

  1. Goodnough LT (guest ed). The new age of iron: evaluation and management of iron-restricted erythropoiesis. Sem Hematol. 2009;46(4):325- 327.
  2. Brugnara C, Laufer MR, Friedman AJ, Bridges K, Platt O. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood. 1994;83(10):3100-3101.
  3. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292-4297.
  4. Auerbach M, Goodnough LT, Picard D, Manaitis A. The role of intravenous iron in anemia man- agement and transfusion avoidance. Transfusion. 2008;48(5):988-1000.
  5. Finch CA. Perspective in iron metabolism. N Engl J Med. 1982;306(25):1520-1528.
  6. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122(2-3):78-86.
  7. Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol (http://www.hindawi.com/journals/ah/). 2010;2010:750643. Accessed December 24, 2010.
  8. Tanno T, Miller JL. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol (http://www.hindawi.com/journals/ah/). 2010;2010:358283. Accessed May 11, 2010.
  9. Weiss G, Goodnough LT. Anemia of chronic dis- ease. N Engl J Med. 2005;352(10):43-55.
  10. Goodnough LT, Skikne B, Brugnara C. Erythro- poietin, iron, and erythropoiesis. Blood. 2000; 96(3):823-833.
  11. Freireich EJ, Miller A, Emerson CP, Ross JF. The effect of inflammation on the utilization of erythro- cyte and transferrin bound radioiron for red cell production. Blood. 1957;12(11):972-983.
  12. Zhang DL, Hughes RM, Ollivierre-Wilson H, Ghosh MC, Rouault TA. A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell Metab. 2009;9(5): 461-473.
  13. Keel SB, Abkowitz JL. The microcytic red cell and the anemia of inflammation. N Engl J Med. 2009; 361(19):1904-1906.
  14. Ali MA, Luxton AW, Walker WH. Serum ferritin concentration and bone marrow iron stores: a prospective study. Can Med Assoc J. 1978;118(8): 945-946.
  15. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44(1):45-51.
  16. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autolo- gous blood donated by orthopedic patients. Transfusion. 1993;33(1):55-60.
  17. Eschbach JW, Haley NR, Egrie JC, Adamson JW. A comparison of the responses to recombinant human erythropoietin in normal and uremic sub- jects. Kidney Int. 1992;42(2):407-416.
  18. Rockey DC, Cello JP. Evaluation of the gastroin- testinal tract in patients with iron-deficiency ane- mia. N Engl J Med. 1993;329(23):1691-1695.
  19. Raje D, Mukhtar H, Oshowo A, Ingham Clark C. What proportion of patients referred to secondary care with iron deficiency anemia have colon can- cer? Dis Colon Rectum. 2007;50(8):1211-1214.
  20. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD. Serum transferrin receptor distin- guishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med. 1992;119(4): 385-390.
  21. Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological dis- orders. Int J Clin Lab Res. 1998;28(1):1-11.
  22. Brugnara C, Colella GM, Cremins J, et al. Effects of subcutaneous recombinant human erythropoi- etin in normal subjects: development of de- creased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med. 1994;123(5):660-667.
  23. Macdougall IC. What is the most appropriate strategy to monitor functional iron deficiency in the dialyzed patients on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Trans- plant. 1998;13(4):847-849.
  24. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expres- sion of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100(10):3776-3781.
  25. Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics. 2010;73(3): 527-536.
  26. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009;4(8):1384-1387.
  27. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and thera- peutic implications. Blood. 2009;113(21):5277- 5286.
  28. Goodnough LT, Nissenson AR, Dubois RW. Ane- mia: not just an innocent bystander? Arch Intern Med. 2003;163(15):1400-1404.
  29. Bonnar J, Goldberg A, Smith JA. Do pregnant women take their iron? Lancet. 1969;1(7592): 457-458.
  30. Young MF, Glahn RP, Ariza-Nieto M, et al. Serum hepcidin is significantly associated with iron ab- sorption from food and supplemental sources in healthy young women. Am J Clin Nutr. 2009; 89(2):533-538.
  31. Annibale B, Capurso G, Chistolini A, et al. Gastro- intestinal causes of refractory iron deficiency ane- mia in patients without gastrointestinal symptoms. Am J Med. 2001;111(6):439-445.
  32. Hershko C, Skikne B. Pathogenesis and manage- ment of iron deficiency anemia: emerging role of celiac disease, helicobacter pylori, and autoim- mune gastritis. Semin Hematol. 2009;46(4):339- 350.
  33. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intrave- nous ferric carboxymaltose injection for iron defi- ciency anemia in heavy uterine bleeding: a ran- domized, controlled trial. Transfusion. 2009;49(12): 2719-2728.
  34. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-7.
  35. Sadjadi SA. Reduction in recombinant human erythropoietin doses by the use of chronic intra- venous iron supplementation. Am J Kidney Dis. 1995;26(6):1000-1001.
  36. Means RT Jr. Commentary: an anemia of chronic disease, after all? J Invest Med. 1999;47(5):203.
  37. Adamson JW. Hyporesponsiveness to erythropoi- esis stimulating agents in chronic kidney disease: the many faces of inflammation. Adv Chron Kid Dis. 2009;16(2):76-82.
  38. Skikne BS, Cook JD. Effect of enhanced erythro- poiesis on iron absorption. J Lab Clin Med. 1992; 120(5):746-751.
  39. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26(6):41-46.
  40. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25(3):433-439.
  41. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the ane- mia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27(2):234-238.
  42. Coyne DW, Kapoian T, Suki N et al. Ferric glu- conate is highly efficacious in anemia hemodialy- sis patients with high serum ferritin and low trans- ferrin saturation. J Am Soc Nephrol. 2007;18(3): 975-984.
  43. Gasche C, Dejaco C, Waldhoer T, et al. Intrave- nous iron and erythropoietin for anemia associ- ated with Crohn disease. A randomized, con- trolled trial. Ann Intern Med. 1997;126(10):782- 787.
  44. Schreiber S, Howaldt S, Schnoor M, et al. Re- combinant erythropoietin for the treatment of ane- mia in inflammatory bowel disease. N Engl J Med. 1996;334(10):619-623.
  45. Weiss G, Houston T, Kastner S, Johrer K, Grunewald K, Brock JH. Regulation of cellular iron metabolism by erythropoietin: activation of iron-regulatory protein and upregulation of trans- ferrin receptor expression in erythroid cells. Blood. 1997;89(2):680-687.
  46. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F. Presence of the iron ex- porter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood. 2005;106(12): 3979-3984.
  47. Auerbach M. Ferumoxytol as a newer, safer easier to administer intravenous iron: yes or no? Am J Kid Dis. 2008;52(5):826-829.
  48. Fishbane J. Upper limit of serum ferritin: misinter- pretation of the 2006 KDOQI anemia guidelines. Semin Dial. 2008;21(3):217-220.
  49. Hillman RS, Henderson PA. Control of marrow production by the level of iron supply. J Clin In- vest. 1969;48(3):454-460.
  50. Hamstra RD, Block MH. Erythropoiesis in re- sponse to blood loss in man. J Appl Physiol. 1969; 27(4):503-507.
  51. Crosby WH. The metabolism of hemoglobin and bile pigment in hemolytic disease. Am J Med. 1955;18(1):112-122.
  52. Beutler E. The utilization of saccharated Fe59 oxide in red cell formation. J Lab Clin Med. 1958; 51(3):415-419.
  53. Wood JK, Milner PF, Pathak UN. The metabolism of iron dextran given as a total-dose infusion to iron deficient Jamaican subjects. Br J Haematol. 1968;14(2):119-129.
  54. Beamish MR, Davies AG, Eakins JD, Jacobs A, Trevett D. The measurement of reticuloendothe- lial iron release using iron-dextran. Br J Haema- tol. 1971;21(6):617-622.
  55. Bentley DP, Williams P. Parenteral iron therapy in the anemia of rheumatoid arthritis. Rheumatol Rehabil. 1982;21(2):88-92.
  56. Auerbach M, Ballard H, Trout JR, et al. Intrave- nous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004; 22(7):1301-1307.
  57. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate sig- nificantly improves response to epoetin alfa ver- sus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12(2):231-242.
  58. Hedenus M, Birgegard G, Nasman P, et al. Addi- tion of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lympho- proliferative malignancies: a randomized multi- center study. Leukemia. 2007;21(4):627-632.
  59. Bastit L, Vandebroek A, Altintas S, et al. Random- ized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa adminis- tered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced ane- mia. J Clin Oncol. 2008;26(10):1611-1618.
  60. Henry DH. Iron or vitamin B12 deficiency in ane- mic cancer patients prior to erythropoiesis- stimulating agent therapy. Community Oncolo- gist. 2007;4:95-101.
  61. Glaspy J, Crawford J, Van Steenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301- 315.
  62. Gilson CR, Kraus TS, Hod EA, et al. A novel mouse model of red blood cell storage and post transfusion in vivo survival. Transfusion. http:// onlinelibrary.wiley.com/laneproxy.stanford.edu/ doi/10.1111/j.1537-2995.2009.02173.x/pdf. Ac- cessed October 21, 2010. · DOI
  63. Jurado RL. Iron, infections, and anemia of inflam- mation. Clin Infect Dis. 1997;25(4):888-895.
  64. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nehrol. 2006;1:S19-S23.
  65. Crosby WH. The rationale for treating iron defi- ciency anemia. Arch Intern Med. 1984;144(3): 471-472.

Cited by

Sorted by citations

Authors
Goodnough, L. T., Nemeth, E., & Ganz, T.
Affiliations
  • Stanford Medicine (US)
  • University of California, Los Angeles (US)
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2010-12-02
Volume
116
Issue
23
Pages
4754-4761
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2010-05-286260
OpenAlex
W2019599941
Cited by
410
References
8
Citations by year
2026: 2 · 2025: 13 · 2024: 18 · 2023: 26 · 2022: 25 · 2021: 26 · 2020: 30 · 2019: 35 · 2018: 39 · 2017: 29 · 2016: 29 · 2015: 36 · 2014: 25 · 2013: 34 · 2012: 26
FWCI
3.89
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Health Sciences › Medicine › Genetics › Hemoglobinopathies and Related Disorders
Keywords
iron-restricted erythropoiesis, iron homeostasis, iron deficiency anemia, inflammatory markers, intravenous iron, anemia management, diagnostic classification
MeSH terms
Iron Deficiencies, Erythropoiesis, Humans, Anemia, Iron-Deficiency, Iron, Dietary

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review